Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

News und Analysen

The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
The 1 Event That Sent NewLink Genetics Corporation Soaring 25% in September
Shares of NewLink Genetics (NASDAQ: NLNK), a small-cap clinical-stage drug developer focused on therapies to treat cancer, skyrocketed by 25% in September, according to data from S&P Global....
13.000 Punkte im Dax – und dann?
13.000 Punkte im Dax – und dann?
13.000 Punkte im Dax sind zum Greifen nahe und jeder wartet gespannt, wann genau die Marke überschritten wird. Was passiert, wenn die Schwelle überschritten wird? Befinden wir uns nicht schon....
3 Stocks That Could Lose You a Lot of Money
3 Stocks That Could Lose You a Lot of Money
Even the most successful investors swing and miss from time to time. It's a big, messy world out there, and no one has all the information they need to scout out only winning stocks for their....
Roundtable: 1 Stock Retirees Should Consider
Roundtable: 1 Stock Retirees Should Consider
Time magazine declares that "70 is the new 50." And just because you're retired doesn't mean it's time to stop investing. In fact, retirement may be the best time to invest in stocks. Seriously,....
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin just might be the most controversial topic in the investing world. Supporters think the cryptocurrency has the potential to disrupt the financial industry. They also point to bitcoin's....
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin just might be the most controversial topic in the investing world. Supporters think the cryptocurrency has the potential to disrupt the financial industry. They also point to bitcoin's....
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin vs. Biotech: Which Is the Smarter Investment?
Bitcoin just might be the most controversial topic in the investing world. Supporters think the cryptocurrency has the potential to disrupt the financial industry. They also point to bitcoin's....
3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
"Dividend Aristocrat" just has a nice ring to it, doesn't it? The "dividend" part sounds great because it means a stock is going to pay you to own it. "Aristocrat" conveys nobility, an elite....
3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now
"Dividend Aristocrat" just has a nice ring to it, doesn't it? The "dividend" part sounds great because it means a stock is going to pay you to own it. "Aristocrat" conveys nobility, an elite....
AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie Inc.'s (NYSE: ABBV) making considerable progress toward reducing its reliance on its top-selling autoimmune disease drug, Humira, and recent patent news that could sideline Humira....
AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie's Fast Becoming a Top Stock to Buy Now
AbbVie Inc.'s (NYSE: ABBV) making considerable progress toward reducing its reliance on its top-selling autoimmune disease drug, Humira, and recent patent news that could sideline Humira....
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
3 Blockbuster Drugs That Still Cost More Than They Should
3 Blockbuster Drugs That Still Cost More Than They Should
Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or....
3 Blockbuster Drugs That Still Cost More Than They Should
3 Blockbuster Drugs That Still Cost More Than They Should
Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or....
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ: CELG) is smaller than Bristol-Myers Squibb (NYSE: BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one key way,....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
Shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX), a clinical-stage biotech, rose 16.3% in September, according to data from S&P Global Market Intelligence. It looks like investors....
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years. The big biotech's stock is up more than 40% so far....
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years. The big biotech's stock is up more than 40% so far....
Where Will Cara Therapeutics Be in 5 Years?
Where Will Cara Therapeutics Be in 5 Years?
Cara Therapeutics (NASDAQ: CARA) has been one of the most exciting biotech stocks to watch in 2017, and the excitement has stemmed from both positive and negative developments. By late June, the....
Should You Sell Celgene Stock Following an Analyst Downgrade?
Should You Sell Celgene Stock Following an Analyst Downgrade?
Celgene Corp.'s (NASDAQ: CELG) is arguably one of the globe's most successful biotech companies, yet analysts at investment researcher Morgan Stanley cut their rating on the company from equal....